ABVC Biopharma reported FY 2025 results showing no revenue, which the company attributed to not receiving any payments from licensees as their funding was still in progress. Net loss for FY 2025 was USD 8.4 million (up 59%), with loss from operations of USD 7.2 million (up 52%). Operating expenses were USD 7.2 million (up 37%), which ABVC said was mainly driven by higher stock-based compensation for consulting services and rent. Interest expense, net, was USD 0.2 million (down 66%). ABVC ended FY 2025 with cash and cash equivalents of USD 0.7 million, restricted cash of USD 0.6 million, and a working deficit of USD 3.7 million (improved 16.3%). Net cash used in operating activities was USD 3.0 million (up 65%), while net cash provided by financing activities was USD 4.6 million (up 134%). On the business side, ABVC highlighted progress in its pipeline and partnering strategy, including a Phase II study for its Vitargus vitreous substitute initiated in Australia and Thailand (started in Q2 2023), continued enrollment activity in the Phase II Part II adult ADHD study for ABV-1505, and its stated plan to seek a large pharmaceutical partner after successful Phase II completion to support Phase III, NDA submission, and commercialization. The filing also discussed multiple licensing agreements signed in 2024, including a global ophthalmology licensing deal with ForSeeCon Eye and several oncology-focused licensing agreements with OncoX, while noting that ABVC did not receive any licensing payments during FY 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABVC Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-023063), on March 03, 2026, and is solely responsible for the information contained therein.
Comments